Enhanced Yield And Structural Integrity In Plasmid Biomanufacturing Employing The PowerS-ITR E. Coli Platform

By Shrey Amin, Ssempa Kisaalita, Sneha Vilayur, Delicia Henriques, Ryan Rubino, Aparna Nandakumar, Murali Jujjavarapu, Aneri Maniar, Philemon Asfeha, Rui Tang

Plasmid DNA is a cornerstone of advanced therapeutics, yet traditional manufacturing faces persistent challenges—low yield, structural instability, and high costs. Recent innovations address these limitations through engineered microbial platforms designed for efficiency and consistency. PowerS-ITR exemplifies this progress by stabilizing inverted terminal repeat (ITR) sequences, a critical feature for gene therapy plasmids, while significantly improving fermentation performance.

Data show a 2–2.5-fold increase in plasmid yield and over 90% supercoiled integrity, compared to commercial strains that often exhibit high recombination rates and structural inconsistencies. These improvements translate into faster processing timelines, reduced batch variability, and enhanced scalability for clinical and commercial production. By minimizing recombination at ITR regions, the platform ensures structural fidelity essential for downstream applications like AAV vector manufacturing.

As demand for high-quality plasmids grows, solutions that combine yield optimization with regulatory compliance and cost efficiency are vital. Explore how advanced strain engineering is redefining plasmid biomanufacturing and accelerating the development of next-generation therapies.